|
February 22, 2001
Running Time: 00:51:14
Pharmaceutical and modified tobacco products designed to reduce the health risks of smoking cannot yet be proved to reduce tobacco-related disease, says a new report from the Institute of Medicine (IOM) of the National Academies. Products developed to lessen the risk of disease by reducing exposure to toxic chemicals are scientifically feasible, but in the absence of rigorous research, no one knows if these products decrease the incidence of tobacco-related disease or actually increase it by encouraging smoking.
Speakers:
Stuart Bondurant, Professor of Medicine, University of North Carolina, Chapel Hill.
|
